Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration

摘要: Abstract Background The combination of purine analogues (PA) and rituximab (chemoimmunotherapy) is considered the treatment choice for CLL. aim this study was to determine whether chemoimmunotherapy prolonged overall survival in patients with CLL from a single center. Patients Methods From 1980 2010, 273 received: (1) PA (n = 159); (2) plus (PA+R) 114). All treated were included analysis, regardless time at which administered, duration therapy, response. Results PA+R groups well balanced demographic, clinical, biologic features. At 8 years, diagnosis group 88% (95% confidence interval [CI], 82-94%) compared 68% CI, 60-76%) ( P  = .8). Conclusion Chemoimmunotherapy effect independent phase disease given.